Healthcare Analysts discuss the recent advances and outlook for treatment for head and neck cancer on an Analyst/Industry conference call to be held on July 15.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOOK:
- HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
- Hookipa Pharma doses first patient in HB-500 trial
- HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
- Hookipa Pharma price target raised to $6 from $5 at H.C. Wainwright
- Hookipa Pharma’s HB-200 Shows Promise in Phase 2 Cancer Trial